Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Stage of Development | 7 | 1 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Therapy Area | 8 | 1 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Indication | 9 | 1 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Companies | 12 | 2 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Products under Development by Universities/Institutes | 14 | 2 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Therapeutics Assessment | 16 | 7 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Companies Involved in Therapeutics Development | 23 | 5 |
| Cytheris SA | 23 | 1 |
| Genexine, Inc. | 24 | 1 |
| GlaxoSmithKline Plc | 25 | 1 |
| OSE Immunotherapeutics | 26 | 1 |
| Pfizer Inc. | 27 | 1 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Drug Profiles | 28 | 11 |
| Antibody to Antagonize IL-7 Receptor Alpha for Rheumatoid Arthritis Drug Profile | 28 | 1 |
| CYT-107 Drug Profile | 29 | 3 |
| EFFI-7H Drug Profile | 32 | 2 |
| GIFT-7 Drug Profile | 34 | 1 |
| GSK-2618960 Drug Profile | 35 | 1 |
| GX-I7 Drug Profile | 36 | 1 |
| PF-06342674 Drug Profile | 37 | 2 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Dormant Projects | 39 | 1 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Discontinued Products | 40 | 1 |
| Interleukin 7 Receptor Subunit Alpha (CD127 or IL7R) Featured News &Press Releases | 41 | 17 |
| Jun 12, 2013: GSK Halts Clinical Trials Of Multiple Sclerosis Drug GSK-2618960 After Fraud Claim | 41 | 1 |
| Oct 24, 2012: Cytheris Announces US Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leucoencephalopathy | 41 | 1 |
| Oct 09, 2012: Cytheris Announces Publication In Blood Demonstrating CYT107 Reverses Lymphopenia And Increases Virus Specific Immunity Post Stem Cell Transplantation | 42 | 1 |
| Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy | 43 | 1 |
| Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients | 43 | 1 |
| Nov 08, 2011: Cytheris Announces Interim Results From ECLIPSE 2 Hepatitis C Multicenter Study Of IL-7 In Chronically Infected Genotype 1 And 4 Nonresponders To Standard Of Care | 44 | 2 |
| Oct 26, 2011: Cytheris Presents Interim Data From ECLIPSE 2 Hepatitis C Multicenter Study At AASLD Annual Meeting | 46 | 1 |
| May 17, 2011: Cytheris And CITN Announce Selection Of Recombinant Interleukin-7 For Initial Studies At Member Institutions | 47 | 1 |
| May 11, 2011: Cytheris, Lyon And ImmunID Announce Initiation Of Phase IIa Combination Trial Of IL-7 And XELODA In Metastatic Breast Cancer Treatment | 48 | 2 |
| Mar 01, 2011: Cytheris Announces Results From Phase IIa Study Of CYT107 | 50 | 1 |
| Dec 07, 2010: Cytheris Announces Interim Phase I Study Results Of CYT107 In Treatment Of Post-Transplant Patients | 51 | 2 |
| Nov 08, 2010: Cytheris' ORVACS Phase II Clinical Study Combines Immunomodulatory Intervention And Antiretroviral Intensification To Attack Viral Reservoir Of HIV Patients | 53 | 1 |
| Oct 19, 2010: Cytheris Initiates ORVACS-Sponsored Phase II Clinical Study To Attack Viral Reservoir Of HIV Patients | 54 | 1 |
| Sep 23, 2010: Cytheris Initiates Phase II Clinical Trial Of CYT107 In Chronically Infected HIV Patients | 55 | 1 |
| Feb 02, 2010: Cytheris Announces Notice Of Allowance For US Patent Covering The Preparation And Uses Of Its Glycosylated Recombinant Human Interleukin-7 (CYT107) | 56 | 2 |
| Appendix | 58 | 2 |
| Methodology | 58 | 1 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 59 | 1 |